Raised 50 million euros thanks to a key investment from Ottobock, now the company’s main investor.
Signature of an exclusive license with the CEA to develop and market the BCI WIMAGINE® brain-computer interface as part of the ARC-BCI™ experimental system.
Arrival of Rob Ten Hoedt, former President of Medtronic and member of the Executive Committee, to the Board of Directors as Chairman.
EINDHOVEN, Netherlands, November 26, 2024 – ONWARD Medical NV (Euronext: ONWD), today provides a business update for the third quarter of 2024.
“We have secured €50 million in additional capital, welcomed Ottobock as a strategic investor and partner, and secured exclusive rights to develop and commercialize superb brain-machine interface technology,” said Dave Marver, CEO of ONWARD Medical. “This quarter was historic both for the company and for our commitment to developing breakthrough therapies for people with spinal cord injuries. »
Highlights:
_ ARC-EX named as one of the best inventions
_ New successful implementation of the ARC-BCI system
_ $1.1 million grant from the Christopher & Dana Reeve Foundation
_ Exclusive license with CEA
_ ARC-EX named one of the best inventions of 2024 by TIME
_ EIC subsidy
…
Attached, the entire press release:
Health
Related News :